Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: DBOT - Demegen, Inc.

No earlier versions found for this Subject.

Return to DBOT - Demegen, Inc.

Demegen, Inc. ( OTCBB: DBOT ): is a clinical stage biopharmaceutical company, which discovers designs and develops natural and novel peptides for the treatment of infectious diseases and cancer. The primary drugs under development target significant markets for which there are few, if any, satisfactory alternatives. These include treatment for oral candidiasis, a disease prevalent in HIV patients, a treatment for Pseudomonas in Cystic Fibrosis patients, a disease that can be fatal to children, and a treatment for glioblastoma.

Website: demegen.com
Stock News: pcquote.com